LXRX Lexicon Pharmaceuticals Inc

$LXRX 🔥🔥🔥 Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with a Overweight rating, PT $8.00.

$LXRX I couldn't tell you when to add any better than when we see humble-bob and Woo_S both coming out to trash the stock. Now it is confirmed, and I added a few more shares of LXRX today using my monthly dividends from YYY. Thank you both so that I don't have to do my DD or read the charts.

$LXRX Who wakes up and says - an investment banker came out yesterday and said this stock will be $8 in a year and there are 4 or so catalysts occurring in next 6 months, but you know what, I think I will sell my stock for $1.82. I just dont understand.

$LXRX get ready for the 2027 blitz! Zynquista decision, HCM results, Novo milestone payout, pilavapadin partnering. All before mid year.

$LXRX Look at the chart its been a while since we had a pull back, part of the process!!! Every time it shoots up nice after!!! Praying for the same again. Only time will tell , i loaded up more today!! Scared money don’t make money!!!!

$LXRX Zynquista should send this flying if the DKA rates are similar to standard of care, FDA won't have ground to refuse it anymore.

$LXRX At this point all we can say is that Lexi has the potential for success, while it has not had any meaningful and sustainable revenue owing its 26-year existence as a public company, and its controlling shareholder seldom defends its SP. As a result, it has become one of the ideal targets for manipulation by hedge funds & MMs. Until Lexi can bring in sustainable revenue with sizable profits, it will remain as an ATM machine for Tutes and MMs. How far is it from decommissioning this generous ATM machine? I think we're just 6 to 8 months away, which is the time span for Zynquista/T1D's NDA resubmission and approval. Afterwards, Inpefa/HCM will add to the mix followed by Pilavapadin/DPNP and LX9851. The bad news is that escalating volatilities will be here to stay, where fundamental and technical analyses mean very little foretelling SP movements. The good news is that 6 months is not very long, when other catalyts such as LX9851 P1 readout & P2 start will hit news stand as well.

$LXRX Added more after a successful day trade on another ticker. Loaded with Lexi across three different accounts. Patience will pay off! 💪

$LXRX My SP prediction: By EOY/26 after the Zynquista/T1D resubmission - $2.50 to $3.50 By EOQ1/27 after Inpefa/HCM readout - $4.00 to $5.00 By EOY/27 after FDA approval of Inpefa for HCM - $6.00 to $8.00 In the meantime, Novo should have advanced LX9851 to P3 trials with approval in 2028 with $1B milestone payments to LXRX - SP > $10.0 The Pilavapadin clinical advancement with a partner or not should add $5.00 to the SP. GLTA and Cheers!

$LXRX I know we’re all frustrated and some might be losing patience, but just remember institutions added 120 mil shares YTD! “Follow the money” is what they say.

$LXRX Long and bullish. Sitting in the doldrums waiting for news that should come in the next couple of months. Wouldn't be completely surprised to see us touch the 1.50s before bouncing back. At this point I'm along for the ride and enjoying the $AMD climb in the meantime. GLTA!

$LXRX Been trading bio stocks for years and have learned that when share price drops like today without no news and no increase in volume, or any reason you should never panic. Sit tight, same old mm shenanigans. I am down to 2 bio stocks...lxrx and cgtx. When I get my target sell I am out of the stock market for good with the only exception of blue chip high dividend paying securities. Way too much manipulation and corruption. On Monday close at 2.04, Tues open at 2.17 then down to 1.91 today? Comoany management doesnt help much either. Investor insecurity is also baked in especially when CEO says things like partnership talks moving along, good news coming soon, fda approval just around the corner and nothing happens. Some people have been chasing lxrx for years. Tock tock..tick tock....2027 or bust.

$LXRX given Novo’s relationship with Steno in Denmark, I assume they may be helping LXRX with the resubmission, and thus, have perspective on how derisked this opportunity is as an adjunct to insulin in T1D. Very easy plug and play, with a lot of optionality and can retire potential liabilities/ milestone payments with obesity

🚨$LXRX $NVO ATTENTION SHOPPERS, NVO GOING PLACES...🚨 Novo secured exclusive worldwide rights to LX9851 for ALL indications 🌎🔥 💊 Oral ACSL5 inhibitor 🎯 Obesity + metabolic disorders 🧬 Potential GLP-1 combo 💰 Up to $1B in milestones + royalties More pipeline optionality. More shots on goal. 📈🐂 $NVO $LXRX looking interesting here 👀 SEC fillings for those that need proof: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000029/exh101novonordisk-exclus.htm ...

$LXRX then why did you put in your AI slop image the words "accelerated approval"? Do you not know the difference between "expedited review" versus the term Approval? Just be honest, you are trying to pump this stock with deceitful language, you've done countless times with your claim that insulin shots will not be needed anymore after Zyn approval. Here's a question for you, what is the standard review period for a class 2 resubmission? The standard review is 6 months or less, with 90% of all class 2 resubmissions being completed at or under 6 months. You are taking a standard practice, and trying to make it appear accelerated, hint, it's not. It's literally SOP for the FDA. To your second point that nobody is modeling the full 1 billion by 2028, maybe look at the pumper image below, and see the pumper propaganda claiming 1 billion by 2028. Stick to making slop images, your grasp of details is not all there.

$LXRX Amazing how when someone wants to steal your shares how the share price can drop creating fear and anxiety. Then once they get then...miraculously a positive press release from Cantor Fitzgerald and back to 2.00! Only speculation because we all know-there isn't any corruption or manipulation in stock trading. Never.

$LXRX Isnt it in the transcript? ZYNQUISTA resubmission potentially around the end of October

$LXRX No recent open-market insider selling of LXRX stock.​ Marketbeat Recent Form 4 filings and aggregated insider data (from sources tracking SEC filings like MarketBeat, OpenInsider, AltIndex, and others) show: 0 open-market sales by insiders in the last 12 months. Marketbeat Activity has been almost entirely purchases.

$LXRX As I mentioned earlier, Lexicon has developed something that is too good to fail. Ultimately, the stock will rise. It is not without reason that institutional ownership stands at 85%. Patience will be rewarded.

$LXRX If my Big Tech positions are printing green, shorty, you already KNOW I’m loading Lexy.... 📈💰😏 Nothing personal — it’s just BIZ... 😎💼 Easy moneyyyyyyyy!!!!! 😂🔥 So… are we printing another million shares AH, or what? 🖨️📊🤣 .... LFG 🚀🐳💰🤑